Reuters logo
BRIEF-Hubei Biocause Pharmaceutical insurance unit's premium income at 40.3 bln yuan in Jan-Sept
October 12, 2017 / 8:48 AM / 12 days ago

BRIEF-Hubei Biocause Pharmaceutical insurance unit's premium income at 40.3 bln yuan in Jan-Sept

Oct 12 (Reuters) - Hubei Biocause Pharmaceutical Co Ltd

* Says insurance unit’s premium income at 40.3 billion yuan ($6.12 billion) in Jan-Sept

Source text in Chinese: bit.ly/2zg1KMx

Further company coverage: ($1 = 6.5875 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below